Overview
MTVA market data
Price History
MTVA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.97 – $19.03 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $7.6 · P/B 3.63.
Company news
MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study CohortsBenzinga · Jul 9, 2026, 12:40 PM
8-K filing — MetaVia Inc. (MTVA)SEC EDGAR · Jul 9, 2026, 12:35 PM
MetaVia Files Prospectus For Offering $4M Common SharesBenzinga · Jul 2, 2026, 8:15 PM
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingGlobenewswire Inc · Jun 26, 2026, 1:15 PM
MetaVia Shareholders Approve Reverse Stock Split; Ratio To Be Between 1-For-5 And 1-For-22, At Board's DiscretionBenzinga · Jun 8, 2026, 8:15 PM
MetaVia Reports Up To 9.1% Weight Loss In Phase 1 DA-1726 Study, Showcases Combination Data For Metabolic Disease Programs At ADA 2026Benzinga · Jun 8, 2026, 12:45 PM
MetaVia To Present Data On Obesity, Metabolic Therapies At Emerging Growth ConferenceBenzinga · Jun 4, 2026, 12:55 PM
MetaVia Highlights New Phase 1 Data On DA-1726, Dual Oxyntomodulin Analog Agonist Targeting GLP1R And GCGR, In Late-Breaking Poster Presentation At EASL 2026Benzinga · May 27, 2026, 12:37 PM
Why MetaVia Stock Is Surging On Friday?Benzinga · May 22, 2026, 4:05 PM
Why MetaVia Stock Is Falling On Thursday?Benzinga · May 21, 2026, 6:35 PM